WO2009026178A3 - High concentration local anesthetic formulations - Google Patents

High concentration local anesthetic formulations Download PDF

Info

Publication number
WO2009026178A3
WO2009026178A3 PCT/US2008/073381 US2008073381W WO2009026178A3 WO 2009026178 A3 WO2009026178 A3 WO 2009026178A3 US 2008073381 W US2008073381 W US 2008073381W WO 2009026178 A3 WO2009026178 A3 WO 2009026178A3
Authority
WO
WIPO (PCT)
Prior art keywords
local anesthetic
high concentration
anesthetic
ameliorate
anesthetic formulations
Prior art date
Application number
PCT/US2008/073381
Other languages
French (fr)
Other versions
WO2009026178A2 (en
Inventor
James N. Campbell
Arthur F. Michaelis
Original Assignee
Arcion Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcion Therapeutics, Inc. filed Critical Arcion Therapeutics, Inc.
Priority to AU2008289109A priority Critical patent/AU2008289109B2/en
Priority to JP2010521214A priority patent/JP5358574B2/en
Priority to CA2696632A priority patent/CA2696632C/en
Priority to EP08798025A priority patent/EP2187969A2/en
Publication of WO2009026178A2 publication Critical patent/WO2009026178A2/en
Publication of WO2009026178A3 publication Critical patent/WO2009026178A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.
PCT/US2008/073381 2007-08-17 2008-08-15 High concentration local anesthetic formulations WO2009026178A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008289109A AU2008289109B2 (en) 2007-08-17 2008-08-15 High concentration local anesthetic formulations
JP2010521214A JP5358574B2 (en) 2007-08-17 2008-08-15 High concentration local anesthetic formulation
CA2696632A CA2696632C (en) 2007-08-17 2008-08-15 High concentration local anesthetic formulations
EP08798025A EP2187969A2 (en) 2007-08-17 2008-08-15 High concentration local anesthetic formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95645807P 2007-08-17 2007-08-17
US60/956,458 2007-08-17

Publications (2)

Publication Number Publication Date
WO2009026178A2 WO2009026178A2 (en) 2009-02-26
WO2009026178A3 true WO2009026178A3 (en) 2009-10-08

Family

ID=40193778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/073381 WO2009026178A2 (en) 2007-08-17 2008-08-15 High concentration local anesthetic formulations

Country Status (6)

Country Link
US (3) US20090048296A1 (en)
EP (1) EP2187969A2 (en)
JP (1) JP5358574B2 (en)
AU (1) AU2008289109B2 (en)
CA (1) CA2696632C (en)
WO (1) WO2009026178A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283177B2 (en) 2007-01-16 2016-03-15 Juventio, Llc Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
WO2008089242A1 (en) 2007-01-16 2008-07-24 Dermworx, Incorporated Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
CA2730787A1 (en) 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
WO2010019953A1 (en) 2008-08-15 2010-02-18 Arcion Therapeutics, Inc. High concentration local anesthetic formulations for treating non-neuropathic pain
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
RU2497679C2 (en) 2008-10-02 2013-11-10 Милан Инк. Method of making multilayer adhesive laminated material
EP2470172A1 (en) * 2009-08-26 2012-07-04 Nuvo Research Inc. Pharmaceutical formulations and methods of use
EP3412279B1 (en) 2010-09-24 2021-02-17 The Brigham and Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
US9271945B2 (en) * 2014-02-04 2016-03-01 Maureen Ann HURLEY Dermal pain relief delivery system
DK3097907T3 (en) * 2015-05-28 2018-12-10 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S A GEL formulation comprising anesthetic and anesthetic agents
US10039830B2 (en) 2016-03-04 2018-08-07 Cetylite Industries, Inc. Topical anesthetic composition
DE202016105646U1 (en) 2016-06-10 2017-09-13 Farco-Pharma Gmbh Medical composition, in particular in the form of a medicinal gel
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
AU2018266131B2 (en) 2017-05-08 2021-07-29 Alivio Therapeutics, Inc. Formulation of nanostructured gels for increased agent loading and adhesion
CN113825495A (en) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 Non-injectable hydrogel formulations for smart release
CN111803632B (en) * 2019-04-09 2022-04-29 北京五和博澳药业股份有限公司 Flavone polyphenol medicine self-emulsifying composition, preparation method thereof, medicine composition and application

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
JPS6185315A (en) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk Sheet-like preparation
US4863721A (en) * 1987-05-22 1989-09-05 The Procter & Gamble Company Reduced stinging antiperspirant compositions
US4752466A (en) * 1987-08-31 1988-06-21 Johnson & Johnson Products, Inc. Thrombin aerosol
US5380754A (en) * 1988-02-29 1995-01-10 Virotex Corporation Topical composition enhancing healing of viral lesions
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
CA1338779C (en) * 1989-03-17 1996-12-10 Harry Hind Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
JP3115625B2 (en) * 1991-03-30 2000-12-11 帝國製薬株式会社 Topical patch containing lidocaine
DK82892D0 (en) * 1992-06-24 1992-06-24 Michael Hansen APPLICATION OF BRAIN ADDITION FROM BEES AND WHEPS FOR THE PREPARATION OF MEDICINAL PRODUCTS TO TREAT INFECTIONS
DE4309830C1 (en) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Transdermal patches for oestradiol admin. - contg. isopropylidene mono- or di-glycerol as penetration enhancer
US5415866A (en) * 1993-07-12 1995-05-16 Zook; Gerald P. Topical drug delivery system
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
DE19526864A1 (en) * 1995-07-22 1997-01-23 Labtec Gmbh Hormone patches
US5667799A (en) * 1995-10-30 1997-09-16 Caldwell; Larry J. Method for treating headache pain with topical local anesthetic compositions
JPH09268123A (en) * 1996-03-30 1997-10-14 Nichiban Co Ltd Cataplasm for local anesthesia
US5814659A (en) * 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition
FR2748207B1 (en) * 1996-05-06 1998-06-12 Cird Galderma COMPOSITION BASED ON A COMPOUND MODULATING THE REACTIVITY OF NERVOUS FIBERS
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
NO312443B1 (en) * 1998-08-26 2002-05-13 Odd A Olsen Spray nozzle device
US6953590B1 (en) * 1998-10-05 2005-10-11 Yutoku Pharmaceutical Ind. Co., Ltd. Tape material for transcutaneous absorption
US6299902B1 (en) * 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
US7018647B1 (en) * 1999-12-27 2006-03-28 Teikoku Seiyaku Co., Ltd Patches for external use
US20020006435A1 (en) * 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
US20030027833A1 (en) * 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
US6894078B2 (en) * 2001-09-17 2005-05-17 James G. Castillo Alcohol based topical anesthetic formulation and method
US6676961B1 (en) * 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
KR101113003B1 (en) * 2003-03-20 2012-02-24 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
ES2535045T3 (en) * 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Uses and compositions for capsaicin administration
US20050014823A1 (en) * 2003-07-17 2005-01-20 Soderlund Patrick L. Topical anesthetic composition and method of administration
JP2006298934A (en) * 2006-06-26 2006-11-02 Larry J Caldwell Method for treating pain of headache by using topical local anesthetic composition
WO2010019953A1 (en) * 2008-08-15 2010-02-18 Arcion Therapeutics, Inc. High concentration local anesthetic formulations for treating non-neuropathic pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARRA, D.E. ET AL.: "Systemic toxicity from topically applied Lidocaine in conjunction with fractional photothermolysis", ARCH. DERMATOL., vol. 142, 2006, pages 1024 - 1026, XP002509848 *
See also references of EP2187969A2 *

Also Published As

Publication number Publication date
JP2010536793A (en) 2010-12-02
JP5358574B2 (en) 2013-12-04
AU2008289109B2 (en) 2012-02-02
EP2187969A2 (en) 2010-05-26
US20150018387A1 (en) 2015-01-15
AU2008289109A1 (en) 2009-02-26
WO2009026178A2 (en) 2009-02-26
CA2696632C (en) 2014-05-27
US20090048296A1 (en) 2009-02-19
US20200338064A1 (en) 2020-10-29
CA2696632A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2009026178A3 (en) High concentration local anesthetic formulations
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2008061625A3 (en) Transdermal therapeutic system for administering the active substance buprenorphine
RS20060605A (en) Topical methadone compositions and methods for using the same
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2009067703A3 (en) Tapentadol compositions
WO2007095615A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain
WO2007112453A3 (en) Methods amd compositions for treating conditions
WO2009114950A8 (en) Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
WO2009026446A3 (en) Hdac inhibitors
WO2009022899A8 (en) Gel containing pirfenidone
WO2009106819A3 (en) Biological materials and uses thereof
MX2012005689A (en) Arachidonic acid analogs and methods for analgesic treatment using same.
MXPA06012206A (en) Ozonidzed pharmaceutical composition and method.
WO2008151040A3 (en) Analgesic coated medical product
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
WO2010010394A3 (en) Local pharmaceutical compositions comprising an extract of spilanthes
WO2009012472A3 (en) Methods and compositions for treating conditions
WO2009092040A3 (en) Topical pain formulation
WO2009122404A3 (en) Device for in situ production and topical administration of allicin
WO2007144889A3 (en) Treatment of neurofibromatosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08798025

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008289109

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010521214

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2696632

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008798025

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008289109

Country of ref document: AU

Date of ref document: 20080815

Kind code of ref document: A